

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, on 27 November 2025, the board of directors of the Company (the “**Board**”) has proposed to amend the current articles of association of the Company (the “**Articles of Association**”).

The Board has considered to amend the Articles of Association in order to, among others, (i) align with the latest legal and regulatory requirements in relation to treasury shares and communication with shareholders by way of website, following the relevant amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Companies Ordinance (Chapter 622 of the Laws of Hong Kong); and (ii) make consequential and other housekeeping amendments to the Articles of Association (collectively, the “**Proposed Amendments**”).

The Proposed Amendments are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at a forthcoming extraordinary general meeting of the Company (the “**EGM**”). A circular containing, among other things, particulars relating to the Proposed Amendments, together with a notice convening the EGM, will be despatched to the Shareholders in due course.

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 27 November 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.